A Study Comparing The Efficacy, Safety And Tolerability Of Latanoprost 75, 100 And 125 ug/ml To Xalatan In The Treatment Of Primary Open-Angle Glaucoma And Ocular Hypertension

Inclusion Criteria: * Male or female, 18 years of age or older. * Primary open angle glaucoma (POAG) or ocular hypertension (OHT) requiring unilateral or bilateral administration of intraocular pressure (IOP) lowering treatment, including patients who were naïve to IOP lowering treatment. * IOP between ≥ 24 mmHg and ≤ 36 mmHg in at least one eye at the 8 AM time point at baseline/randomization. Exclusion Criteria: * Closed/barely open anterior chamber angle or a history of acute angle closure. * A history of discontinued prostaglandin IOP lowering treatment, unless the reason for discontinuation was participation in a clinical study. * Ocular surgery or argon laser trabeculoplasty in one or both eyes within 3 months prior to the screening visit. * Use or anticipated requirement during the study of any topical medication that was known to affect IOP. * Anticipated need to modify systemic medication known to affect IOP (eg, beta-adrenergic antagonists, alpha-adrenergic agonists, calcium channel blockers, angiotension converting enzyme inhibitors, and angiotension II receptor antagonists) during the study period.